Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial

被引：1
|
作者：
Quidde, J. t [1 ]
Becker, S. Hegewisch [2 ]
Graeven, U. [3 ]
Lerchenmueller, C.
Killing, B. [4 ]
Depenbusch, R.
Steffens, C. -C.
Lange, T. [5 ]
Dietrich, G. [6 ]
Stoehlmacher, J. [7 ]
Reinacher, A. [8 ]
Tannapfel, A. [9 ]
Trarbach, T. [10 ]
Marschner, N.
Schmoll, H. J. [11 ]
Hinke, A. [12 ]
Al-Batran, S. -E. [13 ]
Arnold, D. [14 ]
机构：
[1] Univ Hamburg Hosp, Univ Canc Ctr Hamburg, Hamburg, Germany
[2] HOPE, Internal Med Oncol & Hematol, Hamburg, Germany
[3] Kliniken Maria Hilf GmbH, Klin Haematolgie Onkol, Monchengladbach, Germany
[4] Lahn Dill Kliniken, Dept Hematol & Oncol, Wetzlar, Germany
[5] Asklepios Klin Weissenfels, Dept Hematol & Oncol, Weissenfels, Germany
[6] Klinikum Bietigheim, Dept Gastroenterol Hematol & Oncol, Bietigheim, Germany
[7] Tumorgenetik, Bonn, Germany
[8] Ruhr Univ Bochum, Med Univ Klin, Med Dept, Bochum, Germany
[9] Ruhr Univ Bochum, Med Univ Klin, Dept Pathol, Bochum, Germany
[10] IOMEDICO AG, Med Dept, Freiburg, Germany
[11] Martin Luther Univ Halle Wittenberg, Dept Hematol Oncol FG U1 16, Halle, Germany
[12] WiSP GmbH, Res, Langenfeld, Germany
[13] Nordwest Krankenhaus, Med Oncol, Frankfurt, Germany
[14] CUF Hosp Canc Ctr, CUF, Lisbon, Portugal
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw370.105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
557P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Quality of Life (QoL) in patients with metastatic colorectal cancer (mCRC) receiving maintenance therapy after first-line inductive treatment: A QoL analysis from the AIO KRK 0207 phase III trial
    Quidde, J.
    Arnold, D.
    Hegewisch-Becker, S.
    Graeven, U.
    Lerchenmueller, C. A.
    Killing, B.
    Dpenbusch, R.
    Steffens, C. -C
    Lange, T.
    Dietrich, G.
    Marschner, N.
    Al-Batran, S. -E
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 101 - 101
  • [2] Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial
    Quidde, J.
    Hegewisch-Becker, S.
    Graeven, U.
    Lerchenmueller, C. A.
    Killing, B.
    Depenbusch, R.
    Steffens, C. -C.
    Lange, T.
    Dietrich, G.
    Stoehlmacher, J.
    Reinacher, A.
    Tannapfel, A.
    Trarbach, T.
    Marschner, N.
    Schmoll, H. -J.
    Hinke, A.
    Al-Batran, S. -E.
    Arnold, D.
    ANNALS OF ONCOLOGY, 2016, 27 (12) : 2203 - 2210
  • [3] Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial
    Hans-Joachim Schmoll
    Julia Mann
    Fabian Meinert
    Benjamin Garlipp
    Kersten Borchert
    Arndt Vogel
    Eray Goekkurt
    Ulrich Kaiser
    Heinz-Gert Hoeffkes
    Jörn Rüssel
    Stephan Kanzler
    Thomas Edelmann
    Helmut Forstbauer
    Thomas Göhler
    Carla Hannig
    Bert Hildebrandt
    Carsten Roll
    Carsten Bokemeyer
    Jörg Steighardt
    Franziska Cygon
    Stefan Ibach
    Alexander Stein
    Joseph Tintelnot
    British Journal of Cancer, 2024, 130 : 233 - 241
  • [4] Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the AIO KRK 0104 trial.
    Modest, Dominik Paul
    Laubender, Ruediger Paul
    von Weikersthal, Ludwig Fischer
    Vehling-Kaiser, Ursula
    Stauch, Martina
    Hass, Holger
    Dietzfelbinger, Hermann F.
    Oruzio, Daniel V.
    Klein, Stefan
    Zellmann, Klaus
    Decker, Thomas
    Schulze, Mathias
    Abenhardt, Wolfgang
    Puchtler, Gerhard
    Kappauf, Herbert W.
    Mittermueller, Johann
    Haberl, Christopher
    Stintzing, Sebastian
    Mansmann, Ulrich Robert
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial
    Modest, Dominik P.
    Laubender, Ruediger P.
    Stintzing, Sebastian
    Giessen, Clemens
    Schulz, Christoph
    Haas, Michael
    Mansmann, Ulrich
    Heinemann, Volker
    ACTA ONCOLOGICA, 2013, 52 (05) : 956 - 962
  • [6] Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial
    Hegewisch-Becker, Susanna
    Noepel-Duennebacke, Stefanie
    Hinke, Axel
    Graeven, Ullrich
    Reinacher-Schick, Anke
    Hertel, Jan
    Lerchenmueller, Christian A.
    Killing, Birgitta
    Depenbusch, Reinhard
    Al-Batran, Salah-Eddin
    Lange, Thoralf
    Dietrich, Georg
    Tannapfel, Andrea
    Arnold, Dirk
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : 105 - 113
  • [7] Efficacy and quality of life for FOLFOX/bevacizumab plus /- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial
    Schmoll, Hans-Joachim
    Mann, Julia
    Meinert, Fabian
    Garlipp, Benjamin
    Borchert, Kersten
    Vogel, Arndt
    Goekkurt, Eray
    Kaiser, Ulrich
    Hoeffkes, Heinz-Gert
    Ruessel, Joern
    Kanzler, Stephan
    Edelmann, Thomas
    Forstbauer, Helmut
    Goehler, Thomas
    Hannig, Carla
    Hildebrandt, Bert
    Roll, Carsten
    Bokemeyer, Carsten
    Steighardt, Joerg
    Cygon, Franziska
    Ibach, Stefan
    Stein, Alexander
    Tintelnot, Joseph
    BRITISH JOURNAL OF CANCER, 2024, 130 (02) : 233 - 241
  • [8] Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).
    Arnold, Dirk
    Graeven, Ullrich
    Lerchenmuller, Christian A.
    Killing, Brigitta
    Depenbusch, Reinhard
    Steffens, Claus-Christoph
    Al-Batran, Salah-Eddin
    Lange, Thoralf
    Dietrich, Georg
    Stoehimacher, Jan
    Tannapfel, Andrea
    Schmoll, Hans-Joachim
    Reinacher-Schick, Anke
    Hegewisch-Becker, Susanna
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): Results of the AIO KRK 0207 phase III study
    Hegewisch-Becker, S.
    Arnold, D.
    Lerchenmueller, C. A.
    Killing, B.
    Depenbusch, R.
    Steffens, C. -C
    Al-Batran, S. -E
    Lange, T.
    Dietrich, G.
    Stoehlmacher, J.
    Reinacher-Schick, A.
    Tannapfel, A.
    Quidde, J.
    Hinke, A.
    Schmoll, H. -J
    Graeven, U.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 99 - 99
  • [10] Long-term quality of life in patients with metastatic esophagogastric cancer receiving first-line systemic therapy.
    Pape, Marieke
    Vissers, Pauline A. J.
    Slingerland, Marije
    Mohammad, Nadia Haj
    van de Poll-Franse, Lonneke
    Verhoeven, Rob
    van Laarhoven, Hanneke W. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 306 - 306
12345